⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Oncogenexe Biotech Pty Ltd and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Oncogenexe Biotech Pty Ltd
↗Fourways, South Africa
Oncogenexe Biotech is a South African-based biotechnology company focused on oncology innovation and therapeutic development. The company specializes in creating targeted treatments, including antibody-drug conjugates (ADCs), and provides clinical trial services, particularly for solid tumors like triple-negative breast cancer (TNBC) and pancreatic cancer.
Beyond oncology, the firm maintains research portfolios in infectious diseases, cardiometabolic conditions, autoimmune disorders, and neurodegenerative diseases. They utilize advanced genomic analysis techniques, such as Next Generation Sequencing (NGS) and bioinformatics, to support their diagnostic and therapeutic research efforts.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Antibody Drug Conjugate, Monoclonal Antibody
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LINKS
Website:oncogenexe.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Oncogenexe Biotech Pty Ltd. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.